home / stock / srzn / srzn quote
Last: | $9.5499 |
---|---|
Change Percent: | 2.17% |
Open: | $9.93 |
Close: | $9.5499 |
High: | $9.94 |
Low: | $9.3001 |
Volume: | 7,727 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$9.5499 | $9.93 | $9.5499 | $9.94 | $9.3001 | 7,727 | 05-17-2024 |
$10.1499 | $10.09 | $10.1499 | $10.3001 | $9.3001 | 24,935 | 05-16-2024 |
$10.1525 | $9.8801 | $10.1525 | $10.5 | $9.77 | 44,045 | 05-15-2024 |
$10.4495 | $10.1086 | $10.4495 | $10.4495 | $9.6032 | 15,570 | 05-14-2024 |
$10.2899 | $9.935 | $10.2899 | $10.4584 | $9.7303 | 22,202 | 05-13-2024 |
$10.3999 | $9.77 | $10.3999 | $10.3999 | $9.7415 | 22,834 | 05-10-2024 |
$10.2299 | $9.9 | $10.2299 | $10.4463 | $9.61 | 9,635 | 05-09-2024 |
$10.2 | $9.8241 | $10.2 | $10.2 | $9.55 | 1,233 | 05-08-2024 |
$9.96 | $10.01 | $9.96 | $10.2499 | $9.5552 | 14,127 | 05-07-2024 |
$10.2499 | $9.73 | $10.2499 | $10.65 | $9.73 | 5,310 | 05-06-2024 |
$10 | $10.1 | $10 | $10.1 | $10 | 736 | 05-03-2024 |
$10.0999 | $9.7074 | $10.0999 | $10.4 | $9.55 | 3,087 | 05-02-2024 |
$9.89 | $10.6375 | $9.89 | $10.9 | $9.55 | 9,479 | 05-01-2024 |
$10.76 | $9.08 | $10.76 | $11 | $8.93 | 19,511 | 04-30-2024 |
$9.29 | $8.5 | $9.29 | $9.425 | $8.5 | 10,489 | 04-29-2024 |
$8.9799 | $8.14 | $8.9799 | $8.9799 | $8.14 | 11,126 | 04-26-2024 |
$8.61 | $8.35 | $8.61 | $8.81 | $8.35 | 5,086 | 04-25-2024 |
$8.97 | $9.16 | $8.97 | $9.8369 | $8.59 | 8,980 | 04-24-2024 |
$9.01 | $9.25 | $9.01 | $9.25 | $9.01 | 2,309 | 04-23-2024 |
$9.25 | $9.58 | $9.25 | $9.75 | $8.56 | 9,310 | 04-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
Surrozen Inc. Company Name:
SRZN Stock Symbol:
NASDAQ Market:
In preclinical models of cornea endothelial dystrophies, a Surrozen antibody-based Wnt mimetic reduced corneal edema and stimulated endothelial cell proliferation in the cornea Surrozen’s antibody based Wnt mimetic also increased detectable tear volume production in dry eye disea...
SZN-043 Phase 1a clinical trial results to be presented at the 2024 European Association for the Study of the Liver (EASL) in Milan Preclinical data from ARVO 2024 demonstrate the promise of a Surrozen antibody based Wnt mimetic, to activate targeted cell regeneration in cornea endothel...
2024-05-06 10:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...